SNAP reverses chemotherapy resistance in human tumor cells through downregulation of MGMT

Glioblastoma multiforme, or GBM, is the most frequently occurring and gravest primary tumor of the central nervous system in adults. Poor survival rates among patients with GBM are associated with the development of resistance to chemotherapy drug temozolomide (TMZ). A recent study in The FASEB Journal sheds light on a potential strategy to overcome TMZ resistance in GBM cells.